-
A Phase I Open-label Multi-center Clinical Study to Evaluate Safety Tolerability Pharmacokinetics Pharmacodynamics and Preliminary Anti-Tumor Activity of AC176 in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) Who Have Progressed on at Least Two Prior Systemic Therapies
This study is designed for patients diagnosed with metastatic castration resistant prostate cancer (mCRPC).
This is a Phase I, first-in-human, open-label, multi-center dose-escalation study of ...
Phase
Interventional
